Haloperidol Successfully Treated 4 Cases of Cannabinoid Hyperemesis Syndrome That Failed Standard ER Treatments

Four CHS patients who did not respond to standard emergency department antiemetics improved significantly after receiving haloperidol, suggesting dopamine-cannabinoid receptor interactions may explain the treatment's effectiveness.

Witsil, Joanne C et al.·American journal of therapeutics·2017·Preliminary EvidenceCase Report

Withdrawal (166)Appetite (142)Harm Reduction (776)

Quick Facts

Study Type

Case Report

Evidence

Preliminary Evidence

Sample

Not reported

What This Study Found

Four patients with CHS who failed standard emergency department therapy (including conventional antiemetics) showed significant improvement after treatment with haloperidol, an antipsychotic that primarily blocks dopamine D2 receptors.

The authors propose a mechanistic explanation: CHS involves dysregulation of cannabinoid type 1 (CB1) receptors, and recent animal research has revealed complex interactions between dopamine and CB1 signaling. Haloperidol's success may relate to its ability to modulate these dopamine-cannabinoid interactions rather than through its traditional antiemetic mechanism.

The case series highlights a practical clinical point: CHS patients often undergo excessive laboratory and radiographic testing and require hospital admission because standard antiemetics fail. If haloperidol can quickly resolve symptoms in the emergency department, it could reduce unnecessary testing and admission.

Key Numbers

4 patients. All failed standard ED antiemetics. All improved significantly with haloperidol. Complex dopamine-CB1 receptor interactions proposed as mechanism.

How They Did This

Case series of 4 CHS patients treated with haloperidol in the emergency department after failure of standard antiemetic therapy.

Why This Research Matters

CHS remains a diagnostic and therapeutic challenge in emergency departments. Standard antiemetics frequently fail, leading to prolonged ER stays, excessive workups, and hospital admissions. Haloperidol represents a potentially effective, widely available, and inexpensive treatment option.

The Bigger Picture

This case series adds to growing evidence (alongside the systematic review RTHC-01502) that CHS responds better to dopamine-active drugs (haloperidol, droperidol) and benzodiazepines than to traditional antiemetics. The dopamine-cannabinoid receptor interaction hypothesis provides a theoretical framework that could guide future treatment research.

What This Study Doesn't Tell Us

Only 4 cases without controls. Improvement could coincide with natural symptom resolution. Haloperidol has its own side effects (sedation, movement disorders, QT prolongation) that were not discussed. The proposed mechanism is speculative. The optimal haloperidol dose for CHS has not been established.

Questions This Raises

?What is the optimal haloperidol dose for CHS?
?Would other dopamine antagonists (droperidol, olanzapine) work as well?
?Could haloperidol become a first-line CHS treatment in emergency departments?

Trust & Context

Key Stat:: All 4 CHS patients improved with haloperidol after standard antiemetics failed
Evidence Grade:: Preliminary evidence from a small case series.
Study Age:: Published in 2017. Haloperidol for CHS has received increasing clinical attention since.
Original Title:: Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.
Published In:: American journal of therapeutics, 24(1), e64-e67 (2017)
Authors:: Witsil, Joanne C(2), Mycyk, Mark B(2)
Database ID:: RTHC-01554

Evidence Hierarchy

Meta-Analysis / Systematic Review

Randomized Controlled Trial

Cohort / Case-Control

Cross-Sectional / Observational

Case Report / Animal StudyOne case or non-human subjects

This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

What is haloperidol and why does it work for CHS?

Haloperidol is an antipsychotic drug that blocks dopamine D2 receptors. It appears to work for CHS because of complex interactions between the dopamine and cannabinoid receptor systems. Unlike standard antiemetics (which target serotonin or histamine receptors), haloperidol addresses a different part of the vomiting circuitry that is disrupted in CHS.

Should I ask for haloperidol if I go to the ER with CHS?

This case series suggests haloperidol may be effective when standard antiemetics fail for CHS. However, it is a prescription medication with side effects and should be prescribed by a physician. Discussing haloperidol as an option with your ER doctor is reasonable if standard treatments are not working.

Cite This Study

RTHC-01554·https://rethinkthc.com/research/RTHC-01554

APA

Witsil, Joanne C; Mycyk, Mark B. (2017). Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.. American journal of therapeutics, 24(1), e64-e67. https://doi.org/10.1097/MJT.0000000000000157

MLA

Witsil, Joanne C, et al. "Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.." American journal of therapeutics, 2017. https://doi.org/10.1097/MJT.0000000000000157

RethinkTHC

RethinkTHC Research Database. "Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis S..." RTHC-01554. Retrieved from https://rethinkthc.com/research/witsil-2017-haloperidol-a-novel-treatment

Access the Original Study

View on PubMed View via DOI

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.

← Back to Research Database